Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Endura S P A has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner. JONES-FOSTER, ERICA NICOLE is the busiest examiner for this portfolio, and the prosecution activity is located within the distinct art unit. This represents the entirety of the company's current pending prosecution activity. The focused data point suggests that the company's current prosecution efforts are concentrated on the matter within its designated technology area.
For a practitioner, this means that the immediate success of the company's patent strategy depends entirely on the interaction with this examiner. There is no need for cross-examiner coordination or art unit comparison at this stage. The pending office action defines the current scope of the company's engagement with the patent office. This concentration allows for a highly focused prosecution effort. The presence of the distinct art unit confirms that the current work is technically specialized within the administrative group. No other pending office actions exist to complicate the strategy for this portfolio. The current prosecution state is characterized by this narrow technical and administrative focus.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES-FOSTER, ERICA NICOLE | 1 | 48.1% | +44.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18998398 | Novel Esterase Mutants And Uses Thereof As Stereoselective Catalyst | JONES-FOSTER, ERICA NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18998398 | Novel Esterase Mutants And Uses Thereof As Stereoselective Catalyst | JONES-FOSTER, ERICA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18998398 | Novel Esterase Mutants And Uses Thereof As Stereoselective Catalyst | JONES-FOSTER, ERICA NICOLE | 1656 | §101§112 | Non-Final OA | — | Pending | Jan 24, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial